{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-252523","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.889693+00:00","generated_at":"2026-06-10T02:27:22.374034+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Aeglea appoints Cameron Turtle as PEO; discloses substantial doubt about going concern","bullets":["Cameron Turtle appointed principal executive officer effective Oct 6, 2023; previously COO since June 2023.","Company received SEC waiver to file abbreviated financials for Spyre acquisition; net liabilities assumed of $17.0M.","Substantial doubt about going concern if stockholders do not timely approve Series A Preferred Stock conversion.","As of June 22, 2023, Spyre had cash $3.0M and accrued liabilities $20.0M; total acquisition cost was $113.2M.","Company reduced workforce by 83% in April 2023 to ~10 employees; exploring strategic alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-252523","json":"https://secwatch.observer/filing/0001193125-23-252523.json","markdown":"https://secwatch.observer/filing/0001193125-23-252523.md","text":"https://secwatch.observer/filing/0001193125-23-252523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523252523/0001193125-23-252523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523252523/d493616d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:27:22.374034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b36eb11738","claim":"Cameron Turtle was appointed as principal executive officer at Spyre Therapeutics, Inc..","evidence_excerpt":"On October 6, 2023, the Board of Directors (the “Board”) of Aeglea BioTherapeutics, Inc. (the “Company”) appointed Dr. Cameron Turtle, the Company’s Chief Operating Officer, as the principal executive officer of the Company, effective as of the same day.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523252523/0001193125-23-252523-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal executive officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}